Journal
ALZHEIMERS & DEMENTIA
Volume 14, Issue 12, Pages 1663-1673Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jalz.2018.08.004
Keywords
Alzheimer's disease prevention; Clinical precision medicine; Alzheimer's precision medicine; Multidomain interventions; Alzheimer's Prevention Clinic; Personalized medicine; APOE; Preclinical Alzheimer's disease
Categories
Funding
- Zuckerman Family Foundation
- Women's Alzheimer's Movement
- Weill Cornell Medical College Clinical and Translational Science Center (NIH/NCATS) [UL1TR002384]
- NIH [PO1AG026572]
- Rimora foundation
- Washkowitz Family
- Alzheimer's Prevention Clinic, Weill Cornell Memory Disorders Program
- Hilarity for Charity
- NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR002384] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE ON AGING [P01AG026572] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Like virtually all age-related chronic diseases, late-onset Alzheimer's disease (AD) develops over an extended preclinical period and is associated with modifiable lifestyle and environmental factors. We hypothesize that multimodal interventions that address many risk factors simultaneously and are individually tailored to patients may help reduce AD risk. We describe a novel clinical methodology used to evaluate and treat patients at two Alzheimer's Prevention Clinics. The framework applies evidence-based principles of clinical precision medicine to tailor individualized recommendations, follow patients longitudinally to continually refine the interventions, and evaluate N-of-1 effectiveness (trial registered at ClinicalTrials.gov NCT03687710). Prior preliminary results suggest that the clinical practice of AD risk reduction is feasible, with measurable improvements in cognition and biomarkers of AD risk. We propose using these early findings as a foundation to evaluate the comparative effectiveness of personalized risk management within an international network of clinician researchers in a cohort study possibly leading to a randomized controlled trial. (C) 2018 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available